Login / Signup

Comparison of Pharmacokinetic, Pharmacodynamic and Tolerability Profiles of CKD-11101, Darbepoetin Alfa (NESP®) Biosimilar, to Those of NESP® After a Single Subcutaneous or Intravenous Administration to Healthy Subjects.

Inseung JeonJaeseong OhYu-Kyung KwonSeo Hyun YoonJoo-Youn ChoIn-Jin JangKyung-Sang YuSeung Hwan Lee
Published in: Drug design, development and therapy (2021)
After a single IV or SC dose, the CKD-11101 was well tolerated and showed comparable PK and PD characteristics with reference drug.
Keyphrases
  • chronic kidney disease
  • open label
  • high dose
  • placebo controlled
  • low dose
  • double blind
  • study protocol